Combined pretreatment with KGF + PFT-β augments T-cell zone FRC and CCL21 expression after congenic BMT. (A-E) Immunofluorescence staining of peripheral LN cryosections for B220⁺ B cells (green) and gp38⁺ FRCs (red) was used to assess the relative abundance of gp38⁺ FRCs in T-cell zones of (A) unmanipulated, age-/sex-matched B6 control (non-BMT Controls) or BM transplant recipients that were (B) left untreated or treated with (C) KGF, (D) PFT-β, or (E) KGF + PFT-β. (F-J) Immunofluorescence staining of LNs for B220 (green) and CCL21 (blue) in (F) unmanipulated, age-/sex-matched B6 control (non-BMT Controls) or BM transplant recipients that were (G) left untreated or treated with (H) KGF, (I) PFT-β, or (J) KGF + PFT-β. In all merged images, a white, dashed line encircles the B220⁻ T-cell zones. Data are representative of 2 experiments, each with 3 mice per group; *P < .05.